AIHealthcare Analytics

Knowledge Wiki

Wiki › FDA TEMPO Pilot — Generative AI Medical Devices Path to Patients Before Authorization (2026)

FDA TEMPO Pilot — Generative AI Medical Devices Path to Patients Before Authorization (2026)

CONCEPT
Rev 2 Oct 5, 2026 11:28 UTC 1 sources

The FDA has launched the TEMPO (Total Product Life Cycle Advisory) pilot program to create a pre-authorization pathway for generative AI-enabled medical devices. The program aims to accelerate patient access to beneficial AI devices while gathering real-world performance data that informs post-market oversight and future regulatory frameworks. TEMPO allows developers to bring generative AI devices to market before completing full FDA authorization, with the expectation that post-market data collection will inform ongoing regulatory decisions. This represents a significant shift from traditional device authorization, which requires pre-market evidence of safety and effectiveness. The pilot reflects FDA recognition that traditional device regulation moves too slowly for rapidly evolving AI technology, but it also raises questions about post-market accountability, adverse event reporting, and how "real-world evidence" will be collected and evaluated. Healthcare organizations participating in TEMPO pilots will serve as de facto test sites, creating new governance and liability considerations for health systems and clinicians using early-stage AI devices. ---

Sources: harvested
🔒

Subscribe to read full wiki analysis

Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.

View Plans & Subscribe

New users get a 7-day trial — no credit card required.

← Back to Wiki Index